US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Aardvark Therapeutics

5.15

+0.13002.59%

Post-market: 5.150.00000.00%19:30 EDT

Volume:47.91K

Turnover:245.85K

Market Cap:111.74M

PE:-1.61

High:5.29

Open:5.04

Low:4.93

Close:5.02

52wk High:17.94

52wk Low:3.35

Shares:21.70M

Float Shares:11.17M

Volume Ratio:0.27

T/O Rate:0.43%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-3.2080

EPS(LYR):-0.7400

ROE:-66.02%

ROA:-40.38%

PB:1.49

PE(LYR):-6.96

Loading ...

Overview Company News Filings

Aardvark Therapeutics Says FDA Placed Hold on ARD-101 Trials

FDA places full clinical hold on Aardvark's drug for extreme hunger in Prader-Willi syndrome

Aardvark Therapeutics Inc - to Unblind Hero and Ole Trial Data for Ard-101 for Assessment, Determine Next Steps for the Ard-101 Program

THOMSON REUTERS

Aardvark Therapeutics Plans to Unblind Hero and Ole Data to Inform Path Forward Following FDA Clinical Hold

THOMSON REUTERS

Aardvark Therapeutics Inc - FDA Places Full Clinical Hold on Aardvark's Ind for Ard-101

THOMSON REUTERS

Aardvark Therapeutics Plans to Unblind HERO and OLE Data to Inform Path Forward Following FDA Clinical Hold

Aardvark Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

Aardvark Therapeutics price target lowered to $18 from $20 at BofA

Analysts Offer Insights on Healthcare Companies: Aardvark Therapeutics, Inc. (AARD), Prothena (PRTA) and Eli Lilly & Co (LLY)

RBC Capital Reaffirms Their Hold Rating on Aardvark Therapeutics, Inc. (AARD)

Aardvark Therapeutics reports Q1 EPS (99c), consensus (91c)

Aardvark Therapeutics Q1 EPS $(0.99) Misses $(0.90) Estimate

Benzinga Earnings

Aardvark Q1 net loss widens to $21.6 million; R&D expenses rise to $16.6 million

Aardvark Therapeutics Inc Q1 Operating Expenses USD 22.464 Million

THOMSON REUTERS

Aardvark Therapeutics Inc Q1 Income From Operations USD -22.464 Million

THOMSON REUTERS

Aardvark Therapeutics Inc Q1 Net Income USD -21.588 Million VS. Ibes Estimate USD -18.3 Million

THOMSON REUTERS

Press Release: Aardvark Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates

U.S. RESEARCH ROUNDUP-Amazon, Diamondback Energy, Matador Resources

Aardvark Therapeutics Inc : B. Riley Cuts Target Price to $8 From $32

THOMSON REUTERS

B. Riley Adjusts Aardvark Therapeutics Price Target to $8 From $32, Maintains Buy Rating

MT Newswires Live

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Easy breezy. No more feesies.","description":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","keywords":"Tiger Brokers,U.S. stock trading,Hong Kong stock trading,trading U.S. stocks,stock information,stock prices,U.S. stock quotes,U.S. stock trading,Hong Kong stock trading,IPO trading,buying U.S. stocks,global investment","social":{"ogDescription":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.thetigerbrokers.com/stock/AARD/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"NZL","license":"TBKIWI","edition":"fundamental","symbol":"AARD","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"AARD\",,,,,undefined,":{"symbol":"AARD","market":"US","secType":"STK","nameCN":"Aardvark Therapeutics","latestPrice":5.15,"timestamp":1789588800000,"preClose":5.02,"halted":0,"volume":47910,"hourTrading":{"tag":"盘后","latestPrice":5.15,"preClose":5.15,"latestTime":"19:30 EDT","volume":524,"amount":2698.6000000000004,"timestamp":1789601403793,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.02589641434262964,"floatShares":11168300,"shares":21696893,"eps":-3.207951,"marketStatus":"Post-Mkt","change":0.13,"latestTime":"09-16 19:39:30 EDT","open":5.04,"high":5.29,"low":4.93,"amount":245847.24249,"amplitude":0.071713,"askPrice":5.48,"askSize":1,"bidPrice":4.47,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-3.207951,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1789603200000},"marketStatusCode":4,"adr":0,"listingDate":1739509200000,"exchange":"NASDAQ","adjPreClose":5.02,"preHourTrading":{"tag":"盘前","latestPrice":5.02,"preClose":5.02,"latestTime":"09:28 EDT","volume":353,"amount":1731.0099830000001,"timestamp":1789565281037,"change":0,"changeRate":0,"amplitude":0.023566},"postHourTrading":{"tag":"盘后","latestPrice":5.15,"preClose":5.15,"latestTime":"19:30 EDT","volume":524,"amount":2698.6000000000004,"timestamp":1789601403793,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.273175,"impliedVol":1.9044,"impliedVolPercentile":0.7073},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"AARD\",,,,,undefined,":{"symbol":"AARD","floatShares":11168300,"roa":"-40.38%","roe":"-66.02%","lyrEps":-0.74,"volumeRatio":0.273175,"shares":21696893,"dividePrice":0,"high":5.29,"amplitude":0.071713,"preClose":5.02,"low":4.93,"week52Low":3.35,"pbRate":"1.49","week52High":17.94,"institutionHeld":0,"latestPrice":5.15,"committee":0.980198,"eps":-3.207951,"divideRate":0,"volume":47910,"delay":0,"ttmEps":-3.207951,"open":5.04,"prevYearClose":13.125,"prevWeekClose":5.13,"prevMonthClose":6.1,"prevQuarterClose":5.76,"fiveDayClose":4.92,"twentyDayClose":6.145,"sixtyDayClose":4.08},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/AARD\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-11","symbol":"AARD","fiscalQuarterEnding":"2026/06","expectedEps":-0.87,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1786420800000,"reportTimeType":"post","actualEps":-0.66},{"market":"US","date":"2026-05-07","symbol":"AARD","fiscalQuarterEnding":"2026/03","expectedEps":-0.81,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1778126400000,"reportTimeType":"pre","actualEps":-0.99},{"market":"US","date":"2026-03-23","symbol":"AARD","fiscalQuarterEnding":"2025/12","expectedEps":-0.81,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1774238400000,"reportTimeType":"post","actualEps":-0.81},{"market":"US","date":"2025-11-13","symbol":"AARD","fiscalQuarterEnding":"2025/09","expectedEps":-0.82,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1763010000000,"reportTimeType":"post","actualEps":-0.75},{"market":"US","date":"2025-08-13","symbol":"AARD","fiscalQuarterEnding":"2025/06","expectedEps":-0.52,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1755057600000,"reportTimeType":"post","actualEps":-0.66}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"AARD\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"AARD\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/AARD\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"AARD","date":"2026-09-15","current":-1.605386,"percent":0.857868,"low":-51.17654,"twenty":-9.385911,"median":-6.011177,"eighty":-1.969813,"high":-1.08662,"avg":-7.596426,"sd":8.289648,"marketCap":121460895},"quantilePoints":[{"date":"2025-02-21","current":-51.17654,"twenty":-46.993414,"median":-42.216938,"eighty":-39.920668,"marketCap":368880503},{"date":"2025-02-28","current":-39.75453,"twenty":-42.139802,"median":-40.229211,"eighty":-39.232381,"marketCap":286550651},{"date":"2025-03-07","current":-28.243517,"twenty":-40.603022,"median":-39.176012,"eighty":-36.900511,"marketCap":203579269},{"date":"2025-03-14","current":-31.091602,"twenty":-40.336014,"median":-37.766803,"eighty":-30.723725,"marketCap":224108270},{"date":"2025-03-21","current":-27.23482,"twenty":-39.944402,"median":-34.681377,"eighty":-29.198812,"marketCap":196308580},{"date":"2025-03-28","current":-26.404128,"twenty":-39.576524,"median":-30.913597,"eighty":-27.946841,"marketCap":190320955},{"date":"2025-04-04","current":-9.026143,"twenty":-39.119644,"median":-30.068072,"eighty":-27.341623,"marketCap":185830236},{"date":"2025-04-11","current":-7.397773,"twenty":-38.751766,"median":-29.400552,"eighty":-17.252871,"marketCap":152305358},{"date":"2025-04-17","current":-7.977371,"twenty":-38.300819,"median":-28.45119,"eighty":-8.603741,"marketCap":164238114},{"date":"2025-04-25","current":-8.66235,"twenty":-37.766803,"median":-27.946841,"eighty":-8.371497,"marketCap":178340462},{"date":"2025-05-02","current":-11.939711,"twenty":-36.900511,"median":-27.412825,"eighty":-8.371497,"marketCap":245814773},{"date":"2025-05-09","current":-11.307423,"twenty":-34.865316,"median":-26.68597,"eighty":-8.46634,"marketCap":232797221},{"date":"2025-05-16","current":-7.114571,"twenty":-32.693651,"median":-13.552046,"eighty":-8.46634,"marketCap":197215912},{"date":"2025-05-23","current":-7.834638,"twenty":-31.0204,"median":-11.823792,"eighty":-8.360959,"marketCap":217176159},{"date":"2025-05-30","current":-8.061615,"twenty":-30.818661,"median":-11.433881,"eighty":-8.172533,"marketCap":223467976},{"date":"2025-06-06","current":-9.353039,"twenty":-30.367714,"median":-11.107198,"eighty":-8.178795,"marketCap":259266244},{"date":"2025-06-13","current":-8.656453,"twenty":-30.076972,"median":-10.833207,"eighty":-8.210998,"marketCap":239956875},{"date":"2025-06-20","current":-9.454788,"twenty":-30.053238,"median":-10.188135,"eighty":-8.218152,"marketCap":262086713},{"date":"2025-06-27","current":-10.84796,"twenty":-29.697227,"median":-10.664596,"eighty":-8.356744,"marketCap":300705451},{"date":"2025-07-03","current":-10.894921,"twenty":-29.459887,"median":-10.613156,"eighty":-8.365174,"marketCap":302007206},{"date":"2025-07-11","current":-9.861782,"twenty":-29.308323,"median":-10.597502,"eighty":-8.375712,"marketCap":273368592},{"date":"2025-07-18","current":-9.360866,"twenty":-28.618005,"median":-10.433139,"eighty":-8.40036,"marketCap":259483203},{"date":"2025-07-25","current":-10.542714,"twenty":-28.285052,"median":-10.45662,"eighty":-8.474871,"marketCap":292244042},{"date":"2025-08-01","current":-9.4,"twenty":-28.006176,"median":-10.433139,"eighty":-8.577715,"marketCap":260567999},{"date":"2025-08-08","current":-9.368693,"twenty":-27.946841,"median":-10.061366,"eighty":-8.607418,"marketCap":259700162},{"date":"2025-08-15","current":-6.668132,"twenty":-27.567096,"median":-9.861782,"eighty":-8.474871,"marketCap":244307015},{"date":"2025-08-22","current":-5.762071,"twenty":-27.424692,"median":-9.803081,"eighty":-8.329026,"marketCap":211110768},{"date":"2025-08-29","current":-5.027748,"twenty":-27.270421,"median":-9.525229,"eighty":-8.145134,"marketCap":184206621},{"date":"2025-09-05","current":-5.027748,"twenty":-27.074615,"median":-9.478268,"eighty":-8.014507,"marketCap":184206621},{"date":"2025-09-12","current":-4.61321,"twenty":-26.629602,"median":-9.396086,"eighty":-7.797069,"marketCap":169018796},{"date":"2025-09-19","current":-6.685898,"twenty":-23.929853,"median":-9.368693,"eighty":-7.515801,"marketCap":244957921},{"date":"2025-09-26","current":-7.503129,"twenty":-17.043362,"median":-9.298251,"eighty":-7.308831,"marketCap":274899634},{"date":"2025-10-03","current":-9.102059,"twenty":-12.821851,"median":-9.210333,"eighty":-7.389343,"marketCap":333481245},{"date":"2025-10-10","current":-9.824539,"twenty":-12.161077,"median":-9.298251,"eighty":-7.460987,"marketCap":359951454},{"date":"2025-10-17","current":-7.876213,"twenty":-12.040618,"median":-9.212156,"eighty":-7.503145,"marketCap":288568676},{"date":"2025-10-24","current":-6.425331,"twenty":-11.978881,"median":-9.149542,"eighty":-7.334887,"marketCap":235411289},{"date":"2025-10-31","current":-6.194375,"twenty":-11.800608,"median":-9.102059,"eighty":-7.096882,"marketCap":226949500},{"date":"2025-11-07","current":-5.844979,"twenty":-11.619352,"median":-9.083015,"eighty":-6.739195,"marketCap":214148333},{"date":"2025-11-14","current":-6.453893,"twenty":-11.527382,"median":-8.978494,"eighty":-6.599437,"marketCap":236457733},{"date":"2025-11-21","current":-4.209833,"twenty":-11.386619,"median":-8.807467,"eighty":-6.451943,"marketCap":205321954},{"date":"2025-11-28","current":-4.455369,"twenty":-11.26527,"median":-8.719067,"eighty":-6.366112,"marketCap":217297254},{"date":"2025-12-05","current":-5.535729,"twenty":-11.176245,"median":-8.71121,"eighty":-6.20385,"marketCap":269988572},{"date":"2025-12-12","current":-6.968768,"twenty":-11.12541,"median":-8.663092,"eighty":-6.182531,"marketCap":339880775},{"date":"2025-12-19","current":-6.111623,"twenty":-11.06083,"median":-8.610671,"eighty":-6.174808,"marketCap":298076093},{"date":"2025-12-26","current":-6.366088,"twenty":-10.989171,"median":-8.599121,"eighty":-6.172233,"marketCap":310486858},{"date":"2026-01-02","current":-5.859391,"twenty":-10.980741,"median":-8.405995,"eighty":-6.111623,"marketCap":285774195},{"date":"2026-01-09","current":-6.477696,"twenty":-10.894921,"median":-8.362013,"eighty":-6.093766,"marketCap":315930176},{"date":"2026-01-16","current":-6.852697,"twenty":-10.894921,"median":-8.218152,"eighty":-6.111623,"marketCap":334219725},{"date":"2026-01-23","current":-6.732161,"twenty":-10.894921,"median":-8.171191,"eighty":-6.111623,"marketCap":328340941},{"date":"2026-01-30","current":-5.959837,"twenty":-10.857352,"median":-8.086731,"eighty":-6.108052,"marketCap":290673181},{"date":"2026-02-06","current":-5.040192,"twenty":-10.779084,"median":-8.030062,"eighty":-6.020346,"marketCap":245820240},{"date":"2026-02-13","current":-5.482157,"twenty":-10.700911,"median":-7.926792,"eighty":-5.956266,"marketCap":267375780},{"date":"2026-02-20","current":-5.540193,"twenty":-10.673027,"median":-7.864204,"eighty":-5.92323,"marketCap":270206305},{"date":"2026-02-27","current":-5.580372,"twenty":-10.643124,"median":-7.834638,"eighty":-5.890776,"marketCap":272165900},{"date":"2026-03-06","current":-2.562507,"twenty":-10.619417,"median":-7.684115,"eighty":-5.801764,"marketCap":124978581},{"date":"2026-03-13","current":-2.34822,"twenty":-10.594371,"median":-7.524231,"eighty":-5.747859,"marketCap":114527410},{"date":"2026-03-20","current":-2.187506,"twenty":-10.558368,"median":-7.450451,"eighty":-5.647336,"marketCap":106689032},{"date":"2026-03-27","current":-1.329623,"twenty":-10.505146,"median":-7.272172,"eighty":-5.612515,"marketCap":76574303},{"date":"2026-04-02","current":-1.549332,"twenty":-10.461316,"median":-7.114571,"eighty":-5.565193,"marketCap":89227607},{"date":"2026-04-10","current":-1.477359,"twenty":-10.383939,"median":-7.072594,"eighty":-5.510729,"marketCap":85082559},{"date":"2026-04-17","current":-1.890261,"twenty":-10.268548,"median":-6.92859,"eighty":-5.336927,"marketCap":108862044},{"date":"2026-04-24","current":-2.034209,"twenty":-10.187377,"median":-6.86609,"eighty":-5.089336,"marketCap":117152140},{"date":"2026-05-01","current":-2.056938,"twenty":-10.153251,"median":-6.792493,"eighty":-4.960237,"marketCap":118461102},{"date":"2026-05-08","current":-1.748556,"twenty":-10.125375,"median":-6.716536,"eighty":-4.705593,"marketCap":122169829},{"date":"2026-05-15","current":-2.101422,"twenty":-10.043581,"median":-6.685898,"eighty":-4.518505,"marketCap":146824271},{"date":"2026-05-22","current":-1.408234,"twenty":-9.951007,"median":-6.641483,"eighty":-4.307154,"marketCap":98391896},{"date":"2026-05-29","current":-1.311437,"twenty":-9.918135,"median":-6.60716,"eighty":-4.188404,"marketCap":91628817},{"date":"2026-06-05","current":-1.230253,"twenty":-9.857086,"median":-6.549693,"eighty":-2.633043,"marketCap":85956556},{"date":"2026-06-12","current":-1.136579,"twenty":-9.835549,"median":-6.495974,"eighty":-2.45715,"marketCap":79411641},{"date":"2026-06-18","current":-1.192783,"twenty":-9.824539,"median":-6.468768,"eighty":-2.34822,"marketCap":83338590},{"date":"2026-06-26","current":-1.57997,"twenty":-9.822648,"median":-6.449019,"eighty":-2.187506,"marketCap":110390908},{"date":"2026-07-02","current":-1.754828,"twenty":-9.791341,"median":-6.425331,"eighty":-2.13573,"marketCap":122608083},{"date":"2026-07-10","current":-1.561235,"twenty":-9.726041,"median":-6.368321,"eighty":-2.087243,"marketCap":109081925},{"date":"2026-07-17","current":-1.976523,"twenty":-9.645626,"median":-6.354268,"eighty":-2.066183,"marketCap":138097717},{"date":"2026-07-24","current":-1.995258,"twenty":-9.546006,"median":-6.285834,"eighty":-2.034209,"marketCap":139406700},{"date":"2026-07-31","current":-1.998381,"twenty":-9.523603,"median":-6.216183,"eighty":-2.015866,"marketCap":139624864},{"date":"2026-08-07","current":-2.279403,"twenty":-9.505361,"median":-6.182531,"eighty":-2.029869,"marketCap":159259610},{"date":"2026-08-14","current":-2.007209,"twenty":-9.48453,"median":-6.16129,"eighty":-2.029869,"marketCap":140281862},{"date":"2026-08-21","current":-1.844378,"twenty":-9.46418,"median":-6.116088,"eighty":-2.0169,"marketCap":128901742},{"date":"2026-08-28","current":-2.072968,"twenty":-9.421915,"median":-6.102695,"eighty":-2.029869,"marketCap":144877680},{"date":"2026-09-04","current":-1.794276,"twenty":-9.395304,"median":-6.053587,"eighty":-1.99756,"marketCap":125400167},{"date":"2026-09-11","current":-1.568817,"twenty":-9.389042,"median":-6.017873,"eighty":-1.978384,"marketCap":109643078},{"date":"2026-09-15","current":-1.737911,"twenty":-9.385911,"median":-6.011177,"eighty":-1.969813,"marketCap":121460895}],"updateTime":1789601970245},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"AARD\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2635117729","title":"Aardvark Therapeutics Says FDA Placed Hold on ARD-101 Trials","url":"https://stock-news.laohu8.com/highlight/detail?id=2635117729","media":"Dow Jones","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635117729?lang=en_us&edition=fundamental","pubTime":"2026-05-15 05:08","pubTimestamp":1778792880,"startTime":"0","endTime":"0","summary":"Aardvark Therapeutics' drug application for ARD-101, a treatment for people with the genetic disorder Prader-Willi Syndrome, was placed on clinical hold by the Food and Drug Administration.The clinical-stage biopharmaceutical company said after the close Thursday the hold applies to all ongoing clinical studies under the application, including two Phase 3 trials.Shares slid 14% to $5.82 in post-market trading.The hold was related to Aardvark's voluntary pause of one of the Phase 3 trials in February, which it said at the time was due to safety issues in the study.Aardvark is in talks with the FDA to resolve the hold and determine a path forward for ARD-101, it said. The company also plans to unblind the clinical data from both trials to assess efficacy and safety, which it said will help decide next steps for the program.ARD-101 is designed to suppress hunger for the treatment of Prader-Willi Syndrome and metabolic diseases.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AARD","LABU","BK4588","BK4585","BK4007","ARD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635726716","title":"FDA places full clinical hold on Aardvark's drug for extreme hunger in Prader-Willi syndrome","url":"https://stock-news.laohu8.com/highlight/detail?id=2635726716","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635726716?lang=en_us&edition=fundamental","pubTime":"2026-05-15 04:51","pubTimestamp":1778791899,"startTime":"0","endTime":"0","summary":"Aardvark Therapeutics AARD.O on Thursday said the U.S. Food and Drug Administration placed a full clinical hold on its drug to treat extreme hunger linked to the rare disorder Prader-Willi syndrome, halting all late-stage trials.Shares of the company fell about 14% in after-hours trading.Aardvark had paused enrollment and dosing in February after it found heart-related side effects in healthy volunteers given higher-than-planned doses of the drug, ARD-101.The FDA's clinical hold applies to all studies on ARD-101, including a late-stage trial and extension study in Prader-Willi syndrome.The hold follows a previously announced voluntary pause, the company said, adding that it is in active discussions with the regulator to resolve the issue.The drug developer said that 68 patients were dosed in the main study and 19 in the extension as of late February.It added that it would review study data to assess safety and efficacy and determine next steps.Aardvark's ARD-101, being developed as an ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260514:nL4N41R1YO:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AARD","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635728796","title":"Aardvark Therapeutics Inc - to Unblind Hero and Ole Trial Data for Ard-101 for Assessment, Determine Next Steps for the Ard-101 Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2635728796","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635728796?lang=en_us&edition=fundamental","pubTime":"2026-05-15 04:01","pubTimestamp":1778788862,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260514:nTUA2SCRWX:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["AARD","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635728266","title":"Aardvark Therapeutics Plans to Unblind Hero and Ole Data to Inform Path Forward Following FDA Clinical Hold","url":"https://stock-news.laohu8.com/highlight/detail?id=2635728266","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635728266?lang=en_us&edition=fundamental","pubTime":"2026-05-15 04:01","pubTimestamp":1778788862,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260514:nTUA2SCRWX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","AARD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635282247","title":"Aardvark Therapeutics Inc - FDA Places Full Clinical Hold on Aardvark's Ind for Ard-101","url":"https://stock-news.laohu8.com/highlight/detail?id=2635282247","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635282247?lang=en_us&edition=fundamental","pubTime":"2026-05-15 04:01","pubTimestamp":1778788862,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260514:nTUA2SCRWX:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","AARD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635251837","title":"Aardvark Therapeutics Plans to Unblind HERO and OLE Data to Inform Path Forward Following FDA Clinical Hold","url":"https://stock-news.laohu8.com/highlight/detail?id=2635251837","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635251837?lang=en_us&edition=fundamental","pubTime":"2026-05-15 04:01","pubTimestamp":1778788860,"startTime":"0","endTime":"0","summary":"SAN DIEGO, May  14, 2026  (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark or the Company) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecu","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/14/3295315/0/en/Aardvark-Therapeutics-Plans-to-Unblind-HERO-and-OLE-Data-to-Inform-Path-Forward-Following-FDA-Clinical-Hold.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4588","HERO","LABU","IND","BK4007","PWS","AARD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634216183","title":"Aardvark Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2634216183","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634216183?lang=en_us&edition=fundamental","pubTime":"2026-05-12 19:59","pubTimestamp":1778587193,"startTime":"0","endTime":"0","summary":"Aardvark Therapeutics Inc reports results for the quarter ended March 31 - Earnings SummaryAardvark Therapeutics Inc AARD.OQ reported a quarterly adjusted loss of 99 cents per share for the quarter en","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260512:nL8N41P1LS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AARD","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634806428","title":"Aardvark Therapeutics price target lowered to $18 from $20 at BofA","url":"https://stock-news.laohu8.com/highlight/detail?id=2634806428","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634806428?lang=en_us&edition=fundamental","pubTime":"2026-05-10 22:36","pubTimestamp":1778423788,"startTime":"0","endTime":"0","summary":"BofA lowered the firm’s price target on Aardvark Therapeutics (AARD) to $18 from $20 and keeps a Buy rating on the shares. The firm updated the com...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/aardvark-therapeutics-price-target-lowered-to-18-from-20-at-bofa-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/aardvark-therapeutics-price-target-lowered-to-18-from-20-at-bofa-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["AARD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634440999","title":"Analysts Offer Insights on Healthcare Companies: Aardvark Therapeutics, Inc. (AARD), Prothena (PRTA) and Eli Lilly & Co (LLY)","url":"https://stock-news.laohu8.com/highlight/detail?id=2634440999","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634440999?lang=en_us&edition=fundamental","pubTime":"2026-05-10 21:30","pubTimestamp":1778419844,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Aardvark Therapeutics, Inc. (AARD), Prothena (PRTA...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-aardvark-therapeutics-inc-aard-prothena-prta-and-eli-lilly-co-lly-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-aardvark-therapeutics-inc-aard-prothena-prta-and-eli-lilly-co-lly-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IE00B4JS1V06.HKD","LU2265009873.SGD","SGXZ31699556.SGD","LU0320765992.SGD","LU0079474960.USD","LU2264538146.SGD","LU0006306889.USD","LU0354030511.USD","LU0820561818.USD","LU0708995401.HKD","LU1035775433.USD","LU1093756325.SGD","LU0820562030.AUD","LU2112291526.USD","LU2361044949.HKD","LU1917777945.USD","LU2746668461.USD","IE00BJJMRX11.SGD","LU1868837136.USD","LU2236285917.USD","SG9999001176.SGD","LU0320765059.SGD","LU2602419157.SGD","LU1814569148.SGD","IE0005OL40V9.USD","LU0943347566.SGD","LU1720051108.HKD","LU2756315318.SGD","IE00BKDWB100.SGD","LU0109394709.USD","LU0114720955.EUR","LU2468319806.SGD","BK4007","SG9999017495.SGD","LLY","LU1366192091.USD","LU2237443895.HKD","IE00B775H168.HKD","IE00B4R5TH58.HKD","LU1712237335.SGD","LU0672654240.SGD","IE00BJT1NW94.SGD","LU1868836757.USD","LU0823434583.USD","SG9999014914.USD","LU2462157665.USD","IE00BKPKM429.USD","LU2168564222.USD","SG9999015986.USD","LU2357305700.SGD","LU0106261372.USD","LU2471134796.USD","LU1323610961.USD","LU2746668974.SGD","LU1267930730.SGD","IE00B1BXHZ80.USD","LU2271345857.HKD","BK4534","LU2023251221.USD","BK4588","LU2108987350.USD","BK4585","IE0002141913.USD","LU2324357040.USD","LU0234572021.USD","LU2106854487.HKD","LU0097036916.USD","LU2896262040.SGD","LU0096364046.USD","LU1145028129.USD","LU1069344957.HKD","LU2471134879.HKD","SG9999001176.USD","LU0471298777.SGD","LU2213496289.HKD","SGXZ51526630.SGD","LU0964807845.USD","IE00BK4W5M84.HKD","BK4139","IE00BN29S564.USD","LU2361044865.SGD","LU2089984988.USD","LU2361045086.USD","LU2168564065.EUR","IE00B7KXQ091.USD","LU0266013472.USD","LU1064131342.USD","LU0210536198.USD","LU2023250504.SGD","LU1551013342.USD","BK4581","LU0353189680.USD","SG9999013999.USD","LU1623119135.USD","LU0061475181.USD","LU1127390331.HKD","BK4516","LU0122379950.USD","LU1804176565.USD","LU0786609619.USD","LU0640476718.USD","LU2471134952.CNY","LU2063271972.USD","LU2028103732.USD","LU2237443465.HKD","LU1629891620.HKD","LU1868836914.USD","LU0158827948.USD","LU0109391861.USD","BK4533","IE00BJJMRY28.SGD","LLYX","LU0128526141.USD","LU0823416689.USD","LU0889565916.HKD","IE00BWXC8680.SGD","LU2168564495.EUR","LU2237443622.USD","IE0004445239.USD","PRTA","LU0316494557.USD","LU0133085943.USD","LU0256863811.USD","LU0238689110.USD","LU1291159041.SGD","LABU","LU0417517546.SGD","LU2111349929.HKD","LU2168564149.EUR","LU1057294990.SGD","LU2089283258.USD","LU2491050071.SGD","LU2237438978.USD","LU2750360997.AUD","LU0225283273.USD","IE00BFTCPJ56.SGD","LU1548497426.USD","IE0004445015.USD","LU2087625088.SGD","LU0323591593.USD","LU0158827781.USD","LU1093756168.USD","LU1280957306.USD","LU1868836591.USD","GB00BDT5M118.USD","SG9999014898.SGD","LU1974910355.USD","IE00B1XK9C88.USD","SG9999015945.SGD","LU1988902786.USD","LU2552382058.USD","LU0823434740.USD","LU0354030438.USD","SG9999015978.USD","LU0882574139.USD","LU2237443382.USD","LU2237443978.SGD","LU2360106947.USD","IE0001KFT4U8.USD","SGXZ57979304.SGD","SG9999015952.SGD","LU2168563687.JPY","LU0432979614.USD","LU2461242641.AUD","LU0683600562.USD","LU2756315664.SGD","SG9999018865.SGD","IE00BFSS8Q28.SGD","IE00BJJMRZ35.SGD","IE0009355771.USD","LU0094547139.USD","LLYZ","IE00B2B36J28.USD","LU2456880835.USD","AARD","LU1989771016.USD","LU2491050154.USD","XBI","SG9999014906.USD","LU0353189763.USD","LU2750360641.GBP","LU0471298694.HKD","LU2471134523.USD","LU2417539215.USD","SGXZ81514606.USD","LU2552382132.HKD","IE00BFSS7M15.SGD","SGXZ99366536.SGD","LU0029874061.USD","LU0203201768.USD","ELIS","LU1232071149.USD","LU2237443549.SGD","LU2491049909.HKD","LU1551013425.SGD","SG9999014880.SGD","LU0820561909.HKD","BK4137","LU2023250330.USD","IE00BJLML261.HKD","LU2552382215.SGD","SG9999018857.SGD","LU0385154629.USD","BK4599","LU0198837287.USD","ELIL","LU0882574055.USD","LU1868837300.USD","LU2211815571.USD","LU0203202063.USD","LU0289739699.SGD","IE00BK4W5L77.USD","LU0787776722.HKD","LU0058720904.USD","LU0256863902.USD","LU1061106388.HKD","LU1720051017.SGD","LU1023059063.AUD","LU0456855351.SGD","LU0466842654.USD","LU0689472784.USD","LLII","LU1983299246.USD","LU2089284900.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634949646","title":"RBC Capital Reaffirms Their Hold Rating on Aardvark Therapeutics, Inc. (AARD)","url":"https://stock-news.laohu8.com/highlight/detail?id=2634949646","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634949646?lang=en_us&edition=fundamental","pubTime":"2026-05-09 09:55","pubTimestamp":1778291709,"startTime":"0","endTime":"0","summary":"RBC Capital analyst Brian Abrahams maintained a Hold rating on Aardvark Therapeutics, Inc. on May 7 and set a price target of $6.00. The company’s ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/rbc-capital-reaffirms-their-hold-rating-on-aardvark-therapeutics-inc-aard-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/rbc-capital-reaffirms-their-hold-rating-on-aardvark-therapeutics-inc-aard-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["AARD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633173903","title":"Aardvark Therapeutics reports Q1 EPS (99c), consensus (91c)","url":"https://stock-news.laohu8.com/highlight/detail?id=2633173903","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633173903?lang=en_us&edition=fundamental","pubTime":"2026-05-08 03:19","pubTimestamp":1778181563,"startTime":"0","endTime":"0","summary":"“We have been working closely with the FDA to comprehensively evaluate the data following the reversible cardiac observations in the healthy volunt...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/aardvark-therapeutics-reports-q1-eps-99c-consensus-91c-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/aardvark-therapeutics-reports-q1-eps-99c-consensus-91c-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["AARD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633314447","title":"Aardvark Therapeutics Q1 EPS $(0.99) Misses $(0.90) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2633314447","media":"Benzinga Earnings","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633314447?lang=en_us&edition=fundamental","pubTime":"2026-05-07 20:12","pubTimestamp":1778155943,"startTime":"0","endTime":"0","summary":"Aardvark Therapeutics (NASDAQ:AARD) reported quarterly losses of $(0.99) per share which missed the analyst consensus estimate of $(0.90) by 10 percent. This is a 39.44 percent decrease over losses of $(0.71) per share","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/05/52363310/aardvark-therapeutics-q1-eps-0-99-misses-0-90-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AARD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633144161","title":"Aardvark Q1 net loss widens to $21.6 million; R&D expenses rise to $16.6 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2633144161","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633144161?lang=en_us&edition=fundamental","pubTime":"2026-05-07 20:09","pubTimestamp":1778155749,"startTime":"0","endTime":"0","summary":"Aardvark Therapeutics posted a Q1 net loss of USD 21.6 million, widening from USD 9.3 million a year earlier; R&D expense climbed to USD 16.6 million from USD 7.8 million.G&A expense rose to USD 5.9 million from USD 2.7 million.Cash, cash equivalents and short-term investments fell to USD 91.2 million as of March 31 from USD 110 million at year-end; runway projected into mid-2027.Enrollment and dosing remain voluntarily paused in Phase 3 HERO and OLE trials of lead candidate ARD-101 following unexpected reversible cardiac observations in a separate healthy-volunteer study; further guidance expected in Q2 2026.Development of ARD-201 was also voluntarily paused in March; CEO Tien Lee said the company is working with FDA to evaluate data and establish a path forward for the ARD-101 program.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260507:nNDL80mh3n:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BKPKM429.USD","LU2210150020.SGD","BK4588","SG9999014021.USD","IE00BN0W2V16.EUR","BK4112","IE00BN0W2W23.USD","AARD","IE00BGHQF748.EUR","LU2095319765.USD","SG9999014013.SGD","LU2210149790.SGD","SG9999014039.USD","BK4007","NDAQ","IE00B64PRP62.GBP","SG9999014005.SGD","LU0314104364.USD","IE00B3QW5Z07.USD","BK4585","IE00BN0W2T93.GBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633210141","title":"Aardvark Therapeutics Inc Q1 Operating Expenses USD 22.464 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2633210141","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633210141?lang=en_us&edition=fundamental","pubTime":"2026-05-07 20:00","pubTimestamp":1778155204,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260507:nPLXDB9F15:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["AARD","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633141763","title":"Aardvark Therapeutics Inc Q1 Income From Operations USD -22.464 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2633141763","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633141763?lang=en_us&edition=fundamental","pubTime":"2026-05-07 20:00","pubTimestamp":1778155204,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260507:nPLXDB9F15:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["AARD","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633141211","title":"Aardvark Therapeutics Inc Q1 Net Income USD -21.588 Million VS. Ibes Estimate USD -18.3 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2633141211","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633141211?lang=en_us&edition=fundamental","pubTime":"2026-05-07 20:00","pubTimestamp":1778155204,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260507:nPLXDB9F15:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["AARD","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633410771","title":"Press Release: Aardvark Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2633410771","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633410771?lang=en_us&edition=fundamental","pubTime":"2026-05-07 20:00","pubTimestamp":1778155200,"startTime":"0","endTime":"0","summary":"ARD-101 and ARD-201 programs on voluntary pause; further guidance expected in Q2 2026. $91.2 million in cash, cash equivalents and short-term investments as of March 31, 2026, supports projected operations into mid-2027. SAN DIEGO, May 07, 2026  -- Aardvark Therapeutics, Inc.  , a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases, today reported financial results for the first quarter ended March 31, 2026, and provided pipeline and business updates.\"We have been working closely with the FDA to comprehensively evaluate the data following the reversible cardiac observations in the healthy volunteer trial and are committed to determining the best path forward for our programs, patients and the broader PWS community,\" said Tien Lee, M.D., Founder and Chief Executive Officer of Aardvark. \"We remain focused on establishing a clear path forward for the Phase 3 HERO t","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1892829315.USD","LU1803068623.USD","LU0029874061.USD","LU0211327993.USD","BK4007","BK4126","LU1267930490.SGD","LU1989763690.USD","LU0211328371.USD","LU1989763427.SGD","LU0128525929.USD","LU0054578231.USD","LU0708994859.HKD","LU0310800379.SGD","AARD","HERO","LU0310799852.SGD","CCK","PWS","LU0128526141.USD","LU1267930573.SGD","LU0029864427.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622023931","title":"U.S. RESEARCH ROUNDUP-Amazon, Diamondback Energy, Matador Resources","url":"https://stock-news.laohu8.com/highlight/detail?id=2622023931","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622023931?lang=en_us&edition=fundamental","pubTime":"2026-03-25 16:01","pubTimestamp":1774425680,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP-Amazon, Diamondback Energy, Matador ResourcesMarch 25 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies on Wedn","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260325:nL8N40D0JI:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BAM","HD","CNM","DK","FIG","CVX","CVI","AMZP","CALM","ADUS","BPH","FRPT","APEI","AVTX","FIGG","BRZE","ABSI","BTM","KBH","EVGO","INSM","ACAD","GLW","BXP","CEGX","ARE","BCAX","BWXT","DINO","GENB","AMZD","BP","MTDR","AFG","CEG","ELVN","CDE","USAW.SI","HAL","AMZN","AARD","AZYY","AMZU","DG","ESE","BZAI","AVAH","AIR","FANG"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2621206244","title":"Aardvark Therapeutics Inc : B. Riley Cuts Target Price to $8 From $32","url":"https://stock-news.laohu8.com/highlight/detail?id=2621206244","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621206244?lang=en_us&edition=fundamental","pubTime":"2026-03-24 20:40","pubTimestamp":1774356009,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260324:nFWN40C0A0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","AARD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621062681","title":"B. Riley Adjusts Aardvark Therapeutics Price Target to $8 From $32, Maintains Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2621062681","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621062681?lang=en_us&edition=fundamental","pubTime":"2026-03-24 20:30","pubTimestamp":1774355441,"startTime":"0","endTime":"0","summary":"B. Riley Adjusts Aardvark Therapeutics Price Target to $8 From $32, Maintains Buy Rating","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["AARD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":3,"totalSize":78,"code":"91000000","status":"200"}]}}